Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban for Extended Treatment of DVT and PE
NCT00633893Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2008
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial of apixaban in deep vein thrombosis (DVT) and pulmonary embolism (PE) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death at 12 months. Started May 2008; status: completed.
02
Drugs
apixaban
03
Conditions
deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT00633893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00633893.